Soufflé Raises $135 Million for Extrahepatic RNA Delivery

Company Soufflé Therapeutics Event Type Financing (Series B) Modality RNA therapeutics; receptor-mediated extrahepatic siRNA delivery Asset REMEDY product engine; three lead programs (FSHD, heart failure, undisclosed muscle and metabolic target) Target DUX4 (FSHD); phospholamban (cardiomyocytes); undisclosed third target Disease Area Facioscapulohumeral muscular dystrophy; heart failure…